These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [The P 300 potential in schizophrenia]. Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F Encephale; 1993; 19(3):221-7. PubMed ID: 8275907 [TBL] [Abstract][Full Text] [Related]
9. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients. Lindström EM; Ohlund LS; Lindström LH; Ohman A Psychiatry Res; 1992 May; 42(2):145-58. PubMed ID: 1352902 [TBL] [Abstract][Full Text] [Related]
10. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients]. Langlois-Thery S; Dollfus S; Lesieur P; Petit M Encephale; 1994; 20(5):487-93. PubMed ID: 7828511 [TBL] [Abstract][Full Text] [Related]
11. Effect of propranolol and phenothiazines on electrodermal orienting and habituation in schizophrenia. Gruzelier J; Connolly J; Eves F; Hirsch S; Zaki S; Weller M; Yorkston N Psychol Med; 1981 Feb; 11(1):93-108. PubMed ID: 6111100 [TBL] [Abstract][Full Text] [Related]
12. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682 [TBL] [Abstract][Full Text] [Related]
13. [Incidence of the deficit form in refractory schizophrenia]. Samuelian JC Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037 [TBL] [Abstract][Full Text] [Related]
14. [Relationships between insight and medication adherence in subjects with psychosis]. Droulout T; Liraud F; Verdoux H Encephale; 2003; 29(5):430-7. PubMed ID: 14615692 [TBL] [Abstract][Full Text] [Related]
15. An analysis of the skin conductance orienting response in samples of American, British, and German schizophrenics. Bernstein AS; Frith CD; Gruzelier JH; Patterson T; Straube E; Venables PH; Zahn TP Biol Psychol; 1982; 14(3-4):155-211. PubMed ID: 6127121 [TBL] [Abstract][Full Text] [Related]
16. [Psychophysiologic and psychologic correlates of the emotional family climate in schizophrenic patients and their family]. Kraemer S; Hartl L; Böhmer M; Möller HJ Nervenarzt; 1996 Mar; 67(3):219-28. PubMed ID: 8901280 [TBL] [Abstract][Full Text] [Related]
17. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193 [TBL] [Abstract][Full Text] [Related]
18. The relationship of symptomatology and medication to electrodermal activity in schizophrenia. Green MF; Nuechterlein KH; Satz P Psychophysiology; 1989 Mar; 26(2):148-57. PubMed ID: 2567035 [TBL] [Abstract][Full Text] [Related]
19. A significant correlation between ward temperature and the severity of symptoms in schizophrenia inpatients--a longitudinal study. Shiloh R; Munitz H; Stryjer R; Weizman A Eur Neuropsychopharmacol; 2007; 17(6-7):478-82. PubMed ID: 17234387 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the emotional blunting and its prognostic importance during neuroleptic treatment of schizophrenia]. Kukulska D Psychiatr Pol; 2003; 37(6):999-1012. PubMed ID: 14727372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]